Cargando…

Delivery of Cancer Therapeutics Using Nanotechnology

Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Eun-Kyung, Jang, Eunji, Lee, Kwangyeol, Haam, Seungjoo, Huh, Yong-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834952/
https://www.ncbi.nlm.nih.gov/pubmed/24300452
http://dx.doi.org/10.3390/pharmaceutics5020294
_version_ 1782292073752297472
author Lim, Eun-Kyung
Jang, Eunji
Lee, Kwangyeol
Haam, Seungjoo
Huh, Yong-Min
author_facet Lim, Eun-Kyung
Jang, Eunji
Lee, Kwangyeol
Haam, Seungjoo
Huh, Yong-Min
author_sort Lim, Eun-Kyung
collection PubMed
description Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.
format Online
Article
Text
id pubmed-3834952
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38349522013-11-21 Delivery of Cancer Therapeutics Using Nanotechnology Lim, Eun-Kyung Jang, Eunji Lee, Kwangyeol Haam, Seungjoo Huh, Yong-Min Pharmaceutics Review Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems. MDPI 2013-05-15 /pmc/articles/PMC3834952/ /pubmed/24300452 http://dx.doi.org/10.3390/pharmaceutics5020294 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Lim, Eun-Kyung
Jang, Eunji
Lee, Kwangyeol
Haam, Seungjoo
Huh, Yong-Min
Delivery of Cancer Therapeutics Using Nanotechnology
title Delivery of Cancer Therapeutics Using Nanotechnology
title_full Delivery of Cancer Therapeutics Using Nanotechnology
title_fullStr Delivery of Cancer Therapeutics Using Nanotechnology
title_full_unstemmed Delivery of Cancer Therapeutics Using Nanotechnology
title_short Delivery of Cancer Therapeutics Using Nanotechnology
title_sort delivery of cancer therapeutics using nanotechnology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834952/
https://www.ncbi.nlm.nih.gov/pubmed/24300452
http://dx.doi.org/10.3390/pharmaceutics5020294
work_keys_str_mv AT limeunkyung deliveryofcancertherapeuticsusingnanotechnology
AT jangeunji deliveryofcancertherapeuticsusingnanotechnology
AT leekwangyeol deliveryofcancertherapeuticsusingnanotechnology
AT haamseungjoo deliveryofcancertherapeuticsusingnanotechnology
AT huhyongmin deliveryofcancertherapeuticsusingnanotechnology